Table 3 Recommendations for clinical dimensions of major depressive disorder
Dimension | First Intention | Second Intention |
|---|---|---|
With marked anhedonia | SSRI or SNRI | α2-antagonist or agomelatine |
With marked psychomotor retardation | SNRI. SSRI | Tricyclic or α2 antagonists |
With marked sleep disturbances | SSRI or SNRI or α2-antagonist or agomelatine | Tricyclic ADT |
With atypical features (hyperphagia, hypersomnia) | SSRI or SNRI | Tricyclic or agomelatine |
With psychotic features | SNRI in monotherapy or SSRI in combination with an atypical antipsychotic | SSRI, tricyclic ADT or α2-antagonist, in monotherapy or in combination with AAP |
With anxious features | SSRI or SNRI or α2 antagonist | Tricyclic ADT |
With high suicidal risk | SSRI or SNRI or α2 antagonist | Tricyclic ADT or potentiation strategies with lithium or AAP |